首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5906篇
  免费   60篇
  国内免费   63篇
耳鼻咽喉   23篇
儿科学   733篇
妇产科学   207篇
基础医学   533篇
口腔科学   248篇
临床医学   178篇
内科学   1228篇
皮肤病学   274篇
神经病学   158篇
特种医学   115篇
外国民族医学   2篇
外科学   1147篇
综合类   258篇
预防医学   117篇
眼科学   95篇
药学   294篇
中国医学   163篇
肿瘤学   256篇
  2023年   5篇
  2022年   10篇
  2021年   86篇
  2020年   17篇
  2019年   658篇
  2018年   530篇
  2017年   307篇
  2016年   21篇
  2015年   22篇
  2014年   63篇
  2013年   58篇
  2012年   62篇
  2011年   67篇
  2010年   53篇
  2009年   72篇
  2008年   103篇
  2007年   108篇
  2006年   56篇
  2005年   84篇
  2004年   43篇
  2003年   42篇
  2002年   45篇
  2001年   43篇
  2000年   27篇
  1999年   29篇
  1998年   23篇
  1997年   24篇
  1996年   25篇
  1995年   9篇
  1994年   19篇
  1993年   15篇
  1992年   17篇
  1991年   16篇
  1990年   7篇
  1989年   9篇
  1988年   11篇
  1986年   7篇
  1985年   269篇
  1984年   355篇
  1983年   210篇
  1982年   288篇
  1981年   273篇
  1980年   252篇
  1979年   286篇
  1978年   223篇
  1977年   215篇
  1976年   254篇
  1975年   209篇
  1974年   188篇
  1973年   205篇
排序方式: 共有6029条查询结果,搜索用时 10 毫秒
21.
目的探讨调营饮对小鼠S180肝癌腹水模型腹膜淋巴孔的影响。方法取S180细胞接种于小鼠腹腔造成肝癌腹水模型,随机分为空白对照组(NS)、模型组(M)、调营饮低剂量组(TA)、调营饮高剂量组(TB)、模型+NO供组(NO)、调营饮高剂量组+NOS抑制剂组(NOS),造模后第5d用调营饮连续灌胃,观察对小鼠腹膜淋巴孔的影响。结果 TA组和TB组腹膜淋巴孔的平均周长、平均面积和平均密度均明显大于NS组和M组(P〈0.01),NO组腹膜淋巴孔平均周长、平均面积和平均密度明显大于相对应的M组(P〈0.01),NOS组的腹膜淋巴孔平均周长、平均面积和平均密度明显少于相对应的TB组(P〈0.01),TA与TB组比较差异无统计学意义(P〉0.05)。结论调营饮对小鼠S180肝癌腹水模型有明显促进腹膜淋巴孔开放面积增大、周长和分布密度增加的作用,可能是其消腹水作用机制之一。  相似文献   
22.
本文报道了中药雷丸注射液抗小白鼠S_(180)后瘤块的组织学观察。肉眼观察治疗组小鼠的瘤块明显变小;瘤块重量明显减轻,计算其肿瘤生长抑制率为85.2~88%,对照组与治疗组之间有高度显著性差异(P<0.01)。瘤决H.E染色连续切片的光镜观察,有的看不到S_(180)细胞,全部为白细胞巨噬细胞及多核巨细胞浸润,有的只见少量残余的S_(180)细胞小团或小索由大量的上述细胞浸润所包围。此外,可见上述细胞一系列退变解体的组织学改变,瘤块周围的结缔组织及毛细血管向其内增生,并见大量淋巴细胞浸润。  相似文献   
23.
24.
25.
ObjectivesThis study evaluates operative approach and contemporary surgical outcomes in the management of left ventricular outflow tract obstruction by a single surgeon at a high-volume, specialized hypertrophic cardiomyopathy center.MethodsThis is a retrospective review of 1559 consecutive operations for left ventricular outflow tract obstruction from 2005 to 2015. Demographic profiles, echocardiogram-derived ventricular morphology and hemodynamics, operative data, and in-hospital outcomes were analyzed.ResultsOf the 1559 operations, 586 were isolated septal myectomies, 522 were myectomies with mitral valve or subvalvular apparatus intervention, 422 were myectomies with another concomitant procedure, and 29 were isolated mitral valve interventions without myectomy. Common mitral valve interventions included anterior leaflet shortening (16%), chordae tendineae resection (9.8%), papillary muscle resection (7.2%), and papillary muscle reorientation (7.5%). Ninety-two patients underwent mitral valve replacement, 42 for left ventricular outflow tract obstruction and 50 for intrinsic mitral valve pathology. Patients undergoing mitral interventions had thinner septums (18 ± 0.4 mm vs 22 ± 0.5 mm, P < .001) and less myocardium removed (6.2 ± 3.5 g vs 8.8 ± 3.8 g, P < .001) than patients without a mitral intervention. Prevalence of in-hospital permanent pacemaker insertion was 4.2% (n = 1334) for complete heart block and 1.1% (n = 464) for isolated septal myectomy with normal preoperative conduction. Overall, there were 2 postoperative ventricular septal defects (0.13%) and none for isolated myectomies. Operative mortality was 0.38%.ConclusionsSeptal myectomy can be performed safely with excellent outcomes when the procedure is performed by a highly experienced surgeon in a high-volume, specialized center. A mitral valve intervention is a useful adjunct in patients with moderate hypertrophy.  相似文献   
26.
27.
Rabbit pancreatic islet cytosol catalyzes the calcium-activated phosphorylation by [gamma 32P]ATP of a protein with a molecular weight of 57,000 that is precipitated with antipyruvate kinase antibodies. We were unable to demonstrate that phosphorylation in the presence of calcium or cAMP had any immediate effect on rat pancreatic islet pyruvate kinase activity. This finding is consistent with our inability to confirm the finding of others that pancreatic islets contain phosphoenolpyruvate carboxykinase activity (Diabetes, 34:246, 1985). Since the carboxykinase catalyzes phosphoenolpyruvate formation and pyruvate kinase catalyzes essentially the opposite reaction, if the carboxykinase were present in the beta cell, pyruvate kinase would need to be inhibited to prevent recycling of phosphoenolpyruvate.  相似文献   
28.

Objective

Long-term data regarding the safety and durability of thoracic endovascular aortic repair (TEVAR) are limited. The study objective was to evaluate the long-term outcomes of TEVAR in high-risk patients with descending thoracic aortic pathology.

Methods

High-risk patients were treated with thoracic endografts (2001-2011) under a prospective, physician-sponsored, investigational device exemption trial. Three-dimensional reconstructions and measurements were performed on computed tomography scans acquired before discharge, at 1, 6, and 12 months, and then yearly thereafter.

Results

The study included 200 patients, of whom 171 were treated for thoracic aneurysm, 28 for chronic dissection, and 1 for aortobronchial fistula. Patients were monitored for an average of 4.8 ± 3.3 years, and 93 (46.5%) were monitored for >5 years. Operative mortality was 6.5%. Survival at 30 days and at 1, 5, and 9 years was 94.0%, 85.8%, 55.6%, and 31.4%, and freedom from aneurysm-related death was 94.0%, 92.4%, 91.7%, 91.7%, respectively. Sixty-one endoleaks occurred in 54 patients (28%). Sixty-seven reinterventions were performed in 50 patients. Overall freedom from reintervention at 30 days, 1, 5, and 9 years was 87.9%, 82.9%, 75.5%, and 64.0%, respectively. Forty-seven reinterventions (70%) were thoracic aneurysm-related, 35 (74%) of which were endovascular procedures. Thirty of these were to correct endoleaks at a median of 1.4 years (interquartile range, 0.2-5.0 years).

Conclusions

TEVAR is durable and associated with high long-term aneurysm-related survival. Long-term imaging follow-up remains critical to identify endoleaks or rare device durability issues, most of which can be monitored or managed with endovascular therapies.  相似文献   
29.
30.
胡桃楸提取物对S180肉瘤的抑制作用及机制   总被引:5,自引:0,他引:5  
目的:研究胡桃楸提取物(JMME)对小鼠S180肉瘤的抑制作用及其免疫调节用。方法:对 3组荷瘤鼠(每组10只)用0.023、0.045和0.090 g•kg-1•d-1 JMME灌胃给药,同时设阴性对照组和阳性对照组,检测JMME对小鼠体内移植性肿瘤S180肉瘤的抑瘤率;以细胞培养观察JMME对S180细胞生长的抑制作用; MTT法观察JMME对肿瘤坏死因子(TNF)活性和白细胞介素2(IL-2)诱生水平的影响。结果:JMME具有明显的抑制肿瘤的作用,不同浓度的抑瘤率分别为32%、43%和56% ,与阴性对照组比较差异有显著性(P<0.05);对体外培养的肿瘤细胞增殖抑制率可高达60.10%,与对照组比较差异有显著性(P<0.05);TNF活性及IL-2诱生水平较对照组明显增高(P<0.05); 。结论: JMME具有显著抑制肿瘤的作用,其抑瘤作用机制是抑制肿瘤细胞的增殖并调节机体的免疫功能。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号